Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Commentary|Articles|June 6, 2025
Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress
Author(s)Chris Ryan
Fact checked by: Ashling Wahner , Jax DiEugenio
Experts highlight key abstracts to watch for at the 2025 EHA Congress.
Advertisement
Advertisement
The
Related to this article
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Advertisement
Advertisement